Smarter radiation planning aims to boost liver tumor attack while sparing healthy tissue
NCT ID NCT07669727
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 people with a single, untreated liver tumor to see if this approach is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TheraSphere Microspheres (radioactive glass spheres)
What this could lead to
If successful, this could improve how doctors plan radiation for liver cancer, potentially leading to better tumor control with fewer side effects.
What could go wrong
This is a single-arm study with no comparison group, so results may not prove superiority over standard planning. The higher radiation dose could also increase liver damage risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••